Every 8-K that HealthEquity, Inc (HQY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HQY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HQY filings page.
HEALTHEQUITY, INC. (HQY) reported strong results for the second quarter ended July 31, 2026. Revenue was $350.7 million, up 8% year over year, driven by service revenue of $124.4 million, custodial revenue of $175.9 million, and interchange revenue of $50.4 million. Net income rose 10% to $65.6 million, with diluted EPS of $0.78 and a net margin of 19%. Adjusted EBITDA increased 11% to $167.0 million, reaching a record margin of 48%.
HealthEquity ended the quarter with 10.7 million HSAs and Total HSA Assets of $37.9 billion, up 14% year over year, including $17.4 billion in HSA cash and $20.6 billion in HSA investments. The company repurchased 1.2 million shares for $108.1 million, with $948.4 million remaining under its authorization.
For the fiscal year ending January 31, 2027, management raised guidance, targeting revenue of $1.411–$1.421 billion, net income of $242–$248 million (diluted EPS of $2.88–$2.96), non-GAAP net income of $392–$398 million (non-GAAP EPS of $4.66–$4.73), and Adjusted EBITDA of $628–$636 million.
HealthEquity, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 25, 2026. As of the May 6, 2026 record date, 83,830,457 shares of common stock were outstanding and entitled to vote.
Stockholders elected ten directors to serve until the 2027 annual meeting, with each nominee receiving over 74 million votes in favor. They also ratified PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending January 31, 2027, approved on a non-binding basis the fiscal 2026 executive compensation, and authorized a new 2026 Employee Stock Purchase Plan. In addition, stockholders approved the Amended and Restated 2024 Equity Incentive Plan, supporting the company’s long-term equity-based compensation programs.
HealthEquity reported strong results for the quarter ended April 30, 2026, with revenue of $354.6 million, up 7% year over year. Net income rose 29% to $69.4 million, lifting net margin to 20%, while Adjusted EBITDA increased 17% to $164.5 million, or a 46% margin.
Total HSA Assets reached $37.1 billion, up 19%, including $19.6 billion in HSA investments as more members invest their balances. The company repurchased 1.5 million shares for $123.0 million and its board authorized an additional $1.0 billion for future buybacks.
For the fiscal year ending January 31, 2027, management now expects revenue of $1.410 billion to $1.420 billion, net income of $242 million to $248 million (diluted EPS of $2.88 to $2.95), non-GAAP diluted EPS of $4.66 to $4.73, and Adjusted EBITDA of $625 million to $633 million.
HealthEquity, Inc. updated employment and equity award terms for senior executives. On May 5, 2026 the CEO and five other named executives signed amendments providing enhanced severance if the company terminates them without cause or they resign for good reason, including additional salary and bonus protections around a change in control.
The company also approved new vesting rules for future equity awards granted after March 25, 2026. Time-based restricted stock units can accelerate up to one year of scheduled vesting on certain terminations, while performance-based units can continue on a prorated basis and vest based on actual performance results.
HealthEquity, Inc. reported a leadership change in its technology organization. The company will terminate the employment of Chief Technology Officer Eli Rosner without cause, effective April 17, 2026.
Executive Vice President and Chief Product and Strategy Officer Sunil Rajasekar will oversee the company’s technology organization from that date. Mr. Rosner will receive previously negotiated severance payments and benefits under his employment agreement, and his outstanding equity awards will be handled under the company’s 2014 and 2024 Stock Incentive Plans and his award agreements.
HealthEquity, Inc. appointed William “Bill” Gassen, president and chief executive officer of Sanford Health, to its board of directors effective March 26, 2026. His appointment increases the board size to ten directors, eight of whom are independent.
Gassen will serve on the Board’s Audit and Risk Committee and Talent, Compensation and Culture Committee
HealthEquity received $123,923 in revenue from Sanford Health for consumer-directed benefits during the fiscal year ended January 31, 2026, and expects revenue from Sanford Health in the fiscal year ending January 31, 2027 to exceed $120,000. The company furnished a press release about Gassen’s appointment as an exhibit.
HealthEquity, Inc. reported record results for the fiscal year and fourth quarter ended January 31, 2026 and raised its fiscal 2027 outlook. Full-year revenue rose 9% to $1.31 billion, while net income more than doubled to $215.2 million, lifting net margin to 16% from 8%. Adjusted EBITDA grew 20% to $566.0 million, with margin improving to 43%.
Fourth-quarter revenue increased 7% to $334.6 million, and net income rose 89% to $49.7 million. Adjusted EBITDA for the quarter was $132.9 million, up 23%, with margin expanding to 40%. Total HSA Assets reached $36.5 billion, up 14%, and total accounts were 17.8 million.
The company returned $301.7 million to shareholders via repurchases and ended the year with $318.9 million in cash and $957.4 million of debt. For fiscal 2027, it guides revenue to $1.405–$1.415 billion, GAAP net income of $239–$246 million, non-GAAP net income of $392–$400 million, and Adjusted EBITDA of $618–$628 million.
HealthEquity, Inc. reported strong operating metrics for its fiscal year ended January 31, 2026, highlighted by a record fourth quarter for new health savings accounts (HSAs). HSAs reached 10.6 million, up 7% from 9.9 million a year earlier, and Total Accounts grew 4% to 17.8 million. HSA Assets rose 14% to $36.5 billion, with HSA investments increasing 26% year over year to $18.5 billion, reflecting greater use of investment options. The company reaffirmed its outlook for fiscal 2026 and 2027 and stated that fiscal 2026 results should be near the top of prior guidance ranges. HealthEquity also outlined a schedule for repricing $17.3 billion of HSA cash through 2030 and announced the date and time of its March 17, 2026 earnings call and upcoming investor conference appearances.
HealthEquity, Inc. filed a current report to let investors know it has issued a press release with its initial outlook for the fiscal year ending January 31, 2027 and reaffirmed its previously provided guidance for the fiscal year ending January 31, 2026. The outlook and guidance details are contained in the press release attached as Exhibit 99.1.
The company plans to discuss these estimates during a presentation at the 44rd Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 3:00 PM Pacific Time. An audio webcast of the presentation and the related conference materials will be available through the investor section of its website at ir.healthequity.com. The press release is being furnished to regulators, not filed, which means it is not automatically incorporated into other securities law filings.
HealthEquity, Inc. furnished a press release to the SEC as an exhibit to a Form 8-K; the press release is attached as Exhibit 99.1 and the company specifies the exhibit is being furnished rather than filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into other filings unless explicitly stated. The Form 8-K lists the furnishing of the exhibit under the exhibits section and does not include financial statements, earnings data, or other substantive disclosures within the filing text provided here.
HealthEquity (NASDAQ:HQY) filed an 8-K disclosing results of its 26 June 2025 annual meeting and a significant capital-return action.
Shareholder votes: All nine directors were re-elected; PricewaterhouseCoopers LLP was ratified as auditor (82,962,314 for, 346,165 against); and FY-25 executive compensation was approved on an advisory basis (76,093,619 for, 3,218,477 against).
Capital allocation: The board authorized a new $300 million share-repurchase program, supplementing the existing $300 million authorization from August 2024. Repurchases may occur through open-market or privately negotiated transactions, including Rule 10b5-1 plans, and can be suspended at any time.
No other material disclosures were made.